Treatment of oligometastatic disease in colorectal cancer: from molecular biology to multimodal strategies.
- 1Medical Oncology Unit, Azienda Ospedaliera di Rilievo Nazionale Sant'Anna e San Sebastiano Caserta, Casert, Italy.
- 2Interventional Radiology Unit, Azienda Ospedaliera di Rilievo Nazionale Sant'Anna e San Sebastiano Caserta, Casert, Italy.
- 3Pharmacy Unit, Azienda Ospedaliera di Rilievo Nazionale Sant'Anna e San Sebastiano Caserta, Casert, Italy.
Abstract
The management of oligometastatic colorectal cancer (OMD-CRC) has undergone a profound evolution, transforming what was once a uniformly fatal diagnosis into a clinical scenario in which long-term survival and even cure are attainable for a carefully selected subset of patients. This review provides a comprehensive synthesis of integrated, multidisciplinary strategies for OMD-CRC, with particular emphasis on hepatic and pulmonary metastases. We examine the biological foundations that differentiate oligometastatic from polymetastatic disease, including molecular subtypes that inform prognosis and therapeutic responsiveness. Local treatment modalities are critically evaluated, ranging from surgical metastasectomy-the standard of care in adequately selected patients-to minimally invasive approaches such as thermal ablation and Stereotactic Body Radiotherapy (SBRT). Recent randomized trials and prospective studies have suggested possible non-inferiority of these alternatives to surgery in selected contexts, thereby broadening the spectrum of curative-intent interventions. Equally pivotal is the integration of systemic therapy. We discuss optimal timing (neoadjuvant, adjuvant, perioperative) and regimen selection for both resectable and initially unresectable disease. The role of conversion therapy, combining intensive chemotherapy with targeted agents guided by molecular determinants such as RAS/BRAF mutational status and tumor sidedness, is highlighted as a cornerstone in expanding surgical eligibility. Looking ahead, emerging technologies-including radiomics and liquid biopsy approaches such as circulating tumor DNA (ctDNA)-hold promise for refining patient selection, detecting minimal residual disease, and further individualizing treatment pathways. The convergence of advanced local therapies, precision-guided systemic regimens, and novel biomarkers delineates the new frontier in optimizing outcomes for patients with OMD-CRC.
Related
- A Contemporary Review of Resectability and Treatment Strategies for Colorectal Liver Metastases: Part 2-Advanced Surgical Techniques, Conversion Strategies, and the Expanding Boundaries of Treatment.
- Prognostic Significance of the ESTRO/EORTC Classification of Oligometastatic Disease for Colorectal Cancer Patients With Uncommon Metastases Treated With Definitive Radiotherapy
- A Contemporary Review of Resectability and Treatment Strategies for Colorectal Liver Metastases: Part 1—Diagnosis, Defining Resectability, and Management of Upfront Resectable and Synchronous Disease
- Targeting minimal residual disease (MRD) in colorectal cancer: Therapeutic strategies, clinical trials, and the path toward molecular cure
- Personalized Therapeutic Strategies in Glioblastoma: Bridging Molecular Markers and In Vivo Observations for Targeted Treatment
BibTeX
@article{arrichiello2026treatment,
title = {{Treatment of oligometastatic disease in colorectal cancer: from molecular biology to multimodal strategies.}},
author = {G Arrichiello and A Piccolo and F Carlino and E Franzese and A Ventriglia and M Annunziata and V Patanè and M De Siero and M D Bisceglia and M Orditura},
journal = {Oncology reviews},
year = {2026},
month = oct,
doi = {10.3389/or.2026.1932297},
url = {https://europepmc.org/article/MED/42898517},
note = {CC BY},
}
RIS
TY - JOUR
TI - Treatment of oligometastatic disease in colorectal cancer: from molecular biology to multimodal strategies.
AU - G Arrichiello
AU - A Piccolo
AU - F Carlino
AU - E Franzese
AU - A Ventriglia
AU - M Annunziata
AU - V Patanè
AU - M De Siero
AU - M D Bisceglia
AU - M Orditura
PY - 2026
DA - 2026/10/05
JO - Oncology reviews
DO - 10.3389/or.2026.1932297
UR - https://europepmc.org/article/MED/42898517
AB - The management of oligometastatic colorectal cancer (OMD-CRC) has undergone a profound evolution, transforming what was once a uniformly fatal diagnosis into a clinical scenario in which long-term survival and even cure are attainable for a carefully selected subset of patients. This review provides a comprehensive synthesis of integrated, multidisciplinary strategies for OMD-CRC, with particular emphasis on hepatic and pulmonary metastases. We examine the biological foundations that differentiate oligometastatic from polymetastatic disease, including molecular subtypes that inform prognosis and therapeutic responsiveness. Local treatment modalities are critically evaluated, ranging from surgical metastasectomy-the standard of care in adequately selected patients-to minimally invasive approaches such as thermal ablation and Stereotactic Body Radiotherapy (SBRT). Recent randomized trials and prospective studies have suggested possible non-inferiority of these alternatives to surgery in selected contexts, thereby broadening the spectrum of curative-intent interventions. Equally pivotal is the integration of systemic therapy. We discuss optimal timing (neoadjuvant, adjuvant, perioperative) and regimen selection for both resectable and initially unresectable disease. The role of conversion therapy, combining intensive chemotherapy with targeted agents guided by molecular determinants such as RAS/BRAF mutational status and tumor sidedness, is highlighted as a cornerstone in expanding surgical eligibility. Looking ahead, emerging technologies-including radiomics and liquid biopsy approaches such as circulating tumor DNA (ctDNA)-hold promise for refining patient selection, detecting minimal residual disease, and further individualizing treatment pathways. The convergence of advanced local therapies, precision-guided systemic regimens, and novel biomarkers delineates the new frontier in optimizing outcomes for patients with OMD-CRC.
SN - 1970-5565
SN - 1970-5557
ER -